Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Akorn, Inc.    AKRX

AKORN, INC.

(AKRX)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/17/2019 05/20/2019 05/21/2019 05/22/2019 05/23/2019 Date
4.19(c) 4.18(c) 4.39(c) 4.28(c) 4.27(c) Last
973 834 1 531 121 1 772 556 1 299 633 1 323 493 Volume
-1.87% -0.24% +5.02% -2.51% -0.23% Change
More quotes
Financials (USD)
Sales 2019 693 M
EBIT 2019 24,8 M
Net income 2019 -145 M
Debt 2019 -
Yield 2019 -
Sales 2020 710 M
EBIT 2020 124 M
Net income 2020 -49,8 M
Finance 2020 646 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 0,78x
EV / Sales2020 -0,15x
Capitalization 537 M
More Financials
Company
Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The... 
Sector
Pharmaceuticals
Calendar
08/05Earnings Release
More about the company
Surperformance© ratings of Akorn, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on AKORN, INC.
05/21AKORN : Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%
AQ
05/21AKORN : to Present at the RBC Capital Markets Healthcare Conference
AQ
05/20AKORN : Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%
AQ
05/20AKORN : Report of unscheduled material events or corporate event
PU
05/20AKORN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
05/20Akorn to Present at the RBC Capital Markets Healthcare Conference
GL
05/09AKORN : Securities offered to employees pursuant to employee benefit plans
PU
05/09AKORN : Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/07AKORN : Statement of changes in beneficial ownership of securities
PU
05/07AKORN : 1Q Earnings Snapshot
AQ
More news
Analyst Recommendations on AKORN, INC.
More recommendations
Sector news : Pharmaceuticals - NEC
03:22aVECTURA : Awarded $2.5 Million from Novartis After Drug Makes Regulatory Progres..
DJ
05/23GLAXOSMITHKLINE : GSK brings back bonuses for some sales reps
RE
05/23GLAXOSMITHKLINE : GSK's shingles vaccine approved for use in China in adults age..
RE
05/23NOVARTIS : CEO says data quality, lagging innovation crimp China M&A
RE
05/23NOVARTIS : CEO says data quality, lagging innovation crimp China M&A
RE
More sector news : Pharmaceuticals - NEC
Chart AKORN, INC.
Duration : Period :
Akorn, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKORN, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 6,60 $
Spread / Average Target 55%
EPS Revisions
Managers
NameTitle
Douglas S. Boothe President, Chief Executive Officer & Director
Alan D. Weinstein Chairman
Christopher C. Young Executive Vice President-Global Operations
Duane A. Portwood CFO & Executive Vice President
Mark M. Silverberg Executive VP-Operations & Technical Services
Sector and Competitors
1st jan.Capitalization (M$)
AKORN, INC.26.25%537
JOHNSON & JOHNSON7.52%368 416
PFIZER-3.80%233 461
ROCHE HOLDING LTD.9.84%228 186
NOVARTIS13.31%210 460
MERCK AND COMPANY5.98%208 495